Effects of Free Fatty Acids on Glucose Uptake and Utilization in Healthy Women

  1. Carol J. Homko,
  2. Peter Cheung and
  3. Guenther Boden
  1. From the Division of Endocrinology/Diabetes/Metabolism and the General Clinical Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania

    Abstract

    To study effects of sex on free fatty acid (FFA)-induced insulin resistance, we have examined the effects of acute elevations of plasma FFA levels on insulin-stimulated total body glucose uptake in nine healthy young women. Euglycemic-hyperinsulinemic (∼500 pmol/l) clamps were performed for 4 h with coinfusion of either lipid/heparin (L/H) to acutely raise plasma FFA levels (from ∼600 to ∼1,200 μmol/l) or saline/glycerol to lower fatty acids (from ∼600 to ∼50 μmol/l). L/H infusion inhibited insulin-stimulated glucose uptake (determined with [3-3H]glucose) and glycogen synthesis by 31 and 40%, respectively (P < 0.01), almost completely abolished insulin suppression of endogenous glucose production (EGP) (13.6 vs. 10.0 μmol · kg−1 · min−1, NS), prevented the insulin induced increase in carbohydrate oxidation (8.1 vs. 7.4 μmol · kg−1 · min−1, NS), and stimulated fat oxidation (from 3.6 to 5.1 μmol · kg−1 · min−1, P < 0.01). These data showed that acute increases in plasma FFA levels inhibited the actions of insulin on glucose uptake, glycogen synthesis, and EGP in women to a degree similar to that previously reported in men. We conclude that at insulin and FFA levels in the postprandial range, women and men were susceptible to FFA-induced peripheral and hepatic insulin resistance.

    Footnotes

    • Address correspondence and reprint requests to Guenther Boden, Temple University Hospital, 3401 North Broad St., Philadelphia, PA 19140. E-mail: bodengh{at}tuhs.temple.edu.

      Received for publication 9 September 2002 and accepted in revised form 11 November 2002.

      C.J.H. is on advisory panels for Therasense and Amylin and has received honoraria for speaking engagements from Aventis and Disetronic Medical Systems. G.B. is on advisory panels for Novo Nordisk, GlaxoSmithKline, and Aventis; has received honoraria from Novo Nordisk, GlaxoSmithKline, Aventis, and Lilly; and has received grant support from Novo Nordisk.

      EGP, endogenous glucose production; FFA, free fatty acid; GRa, rate of glucose appearance; GRd, rate of glucose disappearance; L/H, lipid/heparin; S/G, saline/glycerol.

    « Previous | Next Article »Table of Contents